Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

LEQEMBI® (lecanemab), a treatment for Alzheimer's disease, is now available in South Korea, expanding access to innovative care

decline through this mechanism. It is estimated there were approximately 900,000 dementia patients in South Korea in 2021,1 with one in ten people over the age of 65 suffering from dementia,1 and one in five from mild cognitive impairment (MCI).2...

Dr. Jonathan Sadeh, ex-SVP of Immunology R&D at Bristol-Myers Squibb, joins Scinai Immunotherapeutics' Scientific Advisory Board

(SAB). In this capacity, Dr Sadeh will play a significant role in advancing the clinical development of Scinai's lead IL-17 program along with other promising assets in their unique VHH antibody pipeline. Dr. Sadeh is an accomplished...

NS Pharma announces a leadership change, appointing new commercial head to drive strategic growth and innovation

(Duchenne), a rare muscle-wasting neurological disorder. Prior to joining NS Pharma, Foy served in leadership roles for 17 years in the pharmaceutical industry, with more than 24 years of experience both in sales and in cross-functional positions...

Niterra Ventures invests an additional $18M in Neoplas Med GmbH, supporting advancements in innovative cancer therapies

technology pioneer Neoplas Med GmbH is intensifying its strategic collaboration with Niterra Ventures Company, via an $18M capital increase to expand the market further for innovative wound care technology products. With a total investment of $25M....

Neurophet gains FDA 510(k) clearance for Neurophet AQUA, advancing multiple sclerosis analysis with AI-driven precision

an artificial intelligence (AI) solution company for brain disease, announced on the "Neurophet AQUA", has obtained 510(k) clearance from U.S. Food and Drug Administration (FDA) for its newly integrated multiple sclerosis (MS) analysis...

Hanmi Pharmaceutical and Beijing Hanmi advance clinical trials for BH3120, their co-developed next-generation cancer immunotherapy

The latest progress in the clinical trial of BH3120, an innovative immunotherapy jointly developed by Hanmi Pharmaceutical and Beijing Hanmi Pharmaceutical, was recently presented at a major global academic conference, drawing significant...

A Korea University study identifies mitochondrial dysfunction as a key factor in cognitive and metabolic impairments, offering insights into potential treatments

truncated, often nonfunctional protein and effectively causing a loss of function. Their study appeared online on November 01, 2024 in the journal Experimental & Molecular Medicine. Highlighting the significance of this achievement, senior author...

Automated red blood cell exchange boosts quality of life for sickle cell patients

Bola Jibodu, a Sickle Cell Warrior from the UK. Especially after a major SCD drug was recently withdrawn from the market,[1] patients will be looking for other options to prevent pain and other dangerous complications from a disease that robs them...

Preclinical study shows NUZ-001 reduces TDP-43 aggregation in ALS

neurodegenerative diseases, is pleased to announce positive results from a preclinical study of its lead candidate, NUZ-001. These innovative studies reveal NUZ-001's unique mechanism of action in preventing the aggregation of TAR DNA-binding...

GenScript's ProBio subsidiary plays a key role in cutting-edge cancer therapies

manufacturing, synthetic biology, and cell therapies announced today that its CDMO subsidiary, ProBio, has licensed its PD-1 new molecular entity (NME) to LaNova Medicines, which recently entered into an agreement with Merck to advance treatment....

Axonal.AI launches an industry-first platform to accelerate life sciences time to market

regulatory demands, and the patent cliff challenge. The McKinsey Global Institute estimates that gen AI could generate $18 billion to $30 billion of economic value in commercial functions at Pharmaceutical and MedTech companies. The Agentic AI...

Orsini begins distribution of CASGEVY® (exagamglogene autotemcel), a gene-editing therapy

(exagamglogene autotemcel). CASGEVY is a CRISPR/Cas9 gene-edited cell therapy indicated for the treatment of patients aged 12 years and older with (1) sickle cell disease (SCD) with recurrent vaso-occlusive crises or (2) transfusion-dependent...

ResQ Pharma receives PDUFA date for LipidRescue™, potentially the first FDA-approved treatment for Local Anesthetic Systemic Toxicity (LAST)

ResQ Pharma, Inc., a Chicago-based pharmaceutical company developing and commercializing innovative drug therapies, today announced that it has received a PDUFA (Prescription Drug User Fee Act) date of June 2, 2025, for its LipidRescue Kit. If...

Bracco Diagnostics Inc. reaches one million injections milestone with its MRI agent, VUEWAY® (gadopiclenol)

(Gd) exposure per MRI procedure without compromising image quality. VUEWAY® (gadopiclenol) solution for injection, 485.1 mg/mL is a macrocyclic gadolinium-based contrast agent (GBCA) that offers effective contrast enhancement at half the gadolinium...

SystImmune secures FDA clearance for BL-M17D1 IND in advanced solid tumors

that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for BL-M17D1, an antibody-drug conjugate (ADC) with a novel linker and payload technology. The IND supports the initiation of a Phase 1...

Transposon to share Phase 2 results of TPN-101 for C9orf72-related ALS/FTD at ALS ONE Research Symposium.

and aging-related diseases, including Alzheimer's disease, announced that results from its Phase 2 study of TPN-101 in patients with amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD) related to hexanucleotide repeat expansion...

Aadi Bioscience reports Q3 2024 financial results and updates on corporate progress

available." Recent Operational Highlights: FYARRO net product sales were $7.2 million in the third quarter, an increase of 17 percent from Q2 2024 and 21 percent compared to the prior-year period. This increase is primarily driven by continued...

HanAll Biopharma releases Q3 2024 financial results and shares business updates

of 2024 and provided business updates. HanAll ended the third quarter with total revenue of 36.8 billion KRW, reflecting an 11.7% increase from the same period in 2023 and an operating profit of 430 million KRW. Pharmaceutical sales reached 34...

Cure51 selects 10x Genomics Visium HD to drive its new drug discovery initiative

French TechBio startup Cure51 and 10x Genomics, Inc., a leader in single cell and spatial biology, announced that Cure51 will deploy 10x Genomics' Visium HD as part of its pioneering work to understand the unique biology of exceptional cancer...

GoodRx debuts a new e-commerce platform, starting with Opill®

growth." The GoodRx and Opill partnership addresses significant gaps in healthcare access, particularly for the more than 19 million women living in areas with limited contraceptive services. By removing major obstacles such as high costs and...